Jackson Jambalaya

 Good job, CDC, good job.  MSN reported: 

The Omicron variant was estimated to be 58.6% of the coronavirus variants circulating in the United States as of Dec. 25, according to data from the U.S. Centers for Disease Control and Prevention (CDC) on Tuesday.

The agency also revised down the Omicron proportion of cases for the week ending Dec. 18 to 22% from 73%, citing additional data and the rapid spread of the variant that in part caused the discrepancy.

"We had more data come in from that timeframe and there was a reduced proportion of Omicron," a CDC spokesperson said. "It’s important to note that we’re still seeing a steady increase in the proportion of Omicron."

The Delta variant, which had been the dominant strain in the past few months, accounts for 41.1% of all U.S. COVID-19 cases as of Dec. 25, the public health agency's data showed.

Former U.S. Food and Drug Administration Commissioner Scott Gottlieb said on Twitter that if the CDC's new estimate of Omicron prevalence was precise, then it suggests that a good portion of the current hospitalizations may still be driven by Delta infections. Rest of article.

Why did yours truly make the "good job" comment? Well, the CDC stopped distributing two of the three monoclonal antibody treatments.  The CDC announced on December 23: 

Circulating SARS-CoV-2 viral variants, including Omicron, may be associated with resistance to monoclonal antibodies. Health care providers should review the Antiviral Resistance information in the Healthcare Provider Fact Sheet for each authorized therapeutic for details regarding specific variants and resistance. The Centers for Disease Control and Prevention (CDC) publishes information about circulating variants in the United States by region. The frequency of the Omicron variant is increasing throughout the U.S. and health care providers should refer to these frequency data as they choose a therapeutic option for their patients.

FDA updated the Health Care Provider Fact Sheets for bamlanivimab and etesevimab administered together, REGEN-COV, and sotrovimab with specific information regarding expected activity against the Omicron variant (B.1.1.529/BA.1). These data show that it is unlikely that bamlanivimab and etesevimab administered together or REGEN-COV will retain activity against this variant. Based on similar cell culture data currently available, sotrovimab appears to retain activity against the Omicron variant.

Based on this information, ASPR will pause any further allocations of bamlanivimab and etesevimab together, etesevimab alone, and REGEN-COV pending updated data from the CDC. Shipments of sotrovimab did resume this week, and delivery of 55,000 doses of product has begun. An additional 300,000 doses of sotrovimab will be available for distribution in January.

The situation varies in different geographic regions and different health care facilities, and there may be circumstances, such as lower frequency of Omicron in a region and limited supply of alternative treatment options, in which the use of existing site supply of these therapeutics is clinically appropriate. We are working to make available the most updated information to health care providers and provide them with appropriate flexibility to provide the best care for their patients. As additional data become available, we will provide updates and further recommendations and consider if additional actions are warranted. ... Rest of press release.